BEAM: Beam Therapeutics Inc.
Performance
BEAM +21.66%
Watchlist
Select an item
Summary
BEAM at a glance
BEAM returned +21.66% over the past year and -21.25% a year over five years. Its worst drop in that year was -39.08%, smaller than 39% of stocks on Redstone, and its Sharpe ratio of 0.57 beats 54% of stocks on Redstone. It pays no dividends.
Current Drawdown
-28.74%
Rolling Volatility
77.83%
Actions
Metrics
Risk Indicators
Alpha20.67%
Beta2.08x
Sharpe0.57
Sortino0.92
Omega1.10
Calmar0.55
Martin1.82
Profile
About BEAM
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $2.8B
- Listed
- Feb 2020
- Employees
- 540
- Headquarters
- Cambridge, MA
- Website
- beamtx.com
Comparisons